Presented by Lee Swanstrom, MD and Bruce Schirmer, MD at the SAGES 2014 Meeting; The Great Presidential Debates of 2014
Dr. Lee Swantsrom’s argument begins: Endoluminal therapies will be the future of early GI cx tx–1:55
disclosures–3:00
ESD–4:00
case 1 example–5:40
case 2 example–7:20
citation–12:17 http://
Keyword(s): abdominal cavity, adenocarcinoma, advanced cx, adverse histopathological findings, adverse pathology markers, Allurion Inc, anastomotic leak, anastomotic stricture, anatomy, Annals of Surgery, annuloplasty, Apollo, balloon dilation, Barcelona trial, Barretts esophagus, Behavioral Risk Factor Surveillance System, benign disease, best case uses, biomarkers, bleeding, blue-dye mapping, Boston Scientific, bowel, bowel tumours, breast cx, breast surgery, British Journal of Surgery, bx, Cardia, case study, Central Surgical Association 2012 presidential address, change, chemotherapy, clinical need, clinical practice, colon cx trials, COLOR, colorectal cx, Colorectal Disease, colorectal surgeon, comorbidity eval, complication rate, consultant, cosmetic argument, cost effective, COST study group trial, Covidien, CT, curative resection, cure rates, cx prevention, cx screening, diagnostics, disease free survival, disfiguring, duodenum, early intervention, efficacy, EMR, en bloc ESD, endolumenal, endoluminal removal, endoluminal staplers, endoluminal therapies, endoscopy, energy sources, epidemiology, ESD, esophageal cx, esophageal surgeon, esophagectomy, esophagus, Ethicon, Europe, EUS, experimental studies, extended mucosectomy, extraluminal disease, extraluminal nodal disease, F/U, fat, financial viability, flex mediastinoscopy, foregut, FTR, FTRD, full thickness resection, gastric cx, gastric outlet obstruction, gastroduodenal artery, GB cx, GEJ, genetic detection, genetic profile, genetic profiling, genetics, GERD, GI cx, GI neoplasia, GI system, GI tract, guidelines, health insurance, HGD, hindgut, ileus, image guided staging, imaging studies, innovative, intestinal cx, intestinal nodes, intraluminal lesions, invasion, invasive adenocarcinoma, Japan, Journal of Surgical Oncology, Journal of the NCI, Lancet Oncology, lap assisted surgery, lap colectomy, lap resection, lap surgery, laparoscopy, life-threatening disease, limitations, liver, liver resection, LN, LN metastasis, local disease, local spread, long-term outcome, LOS, lumpectomy, lympadenectomy, lymphadenectomy, lymphatic system, M&M, male, malignant disease, margins, mass, Medical Research Concil CLASICC trial, mesenteric assessment, mesentery, metastasis, micro hip arthroplasty, Midwestern Surgical, MIE, minimally invasive colectomy, Miret Surgical, MIS, morbidity, mortality rate, mortality rates, mucosa, mucosal cx, multicentre, MVR, node-positive colonic cx, obstructing lesion, obstruction, Olympus, oncologic surgery, open surgery, operator dependent, organ sparing approaches, organ sparing disease, outcomes, outpt procedure, outpt visits, pathology, perf, peritoneal cavity, PET, PNA, polyp, port site metastasis, premalignant lesions, primary tx, prognosis, prospective, prostatectomy, proven tx, pt management, pt pool, pylorus, radical hip replacement, radical mastectomy, radical surgery, radium seed implant, randomised clinical trial, RCT, readmissions, recovery, rectal cx, recurrence, reflux disease, regional spread, research support, RFA, risk profiling, risk stratification, SAB, SAGES great presidential debates of 2014, SAGES members, screening, segmental resection, sentinel lymphadenectomy, sentinel node, sentinel node bx, seromuscular involvement, sigmoid colon, SILS, sleeve resection, SM1, SM1 lesion, SM2, SM3, snare, Spain, specimen, spillage, stage III disease, stage IV disease, staging, standard of care, stomach, stricture rate, submucosa, submucosal cx, submucosal lesions, Surgery, surgical innovation, survival stats, T1, T1b, tachyarrhythmia, TEM, thoracoscopic, TME, transanal endoscopic excision, TransEnterix, transverse closure, tubular adenoma, U.K., U.S., USGI Medical Inc, virtuoso techniques, whipples, wide resection, x-ray
